We have highly advanced global pharmaceutical manufacturing capabilities which include active pharmaceutical ingredients (API), oral solid dose (OSD), injectables, biosimilars, and plasma products. We have fourteen manufacturing facilities, of which eleven are located in India and the rest in the UK and Mexico. These facilities serve a number of markets around the world and produce medicines covering almost all major therapeutic areas. Our ‘Make It Better” philosophy defines our operational actions and ambitions. We strictly comply with environmental health and safety standards at each of our locations and proudly take the lead in ensuring sustainable practices.
We also have an advanced analytical lab and state-of-the-art distribution centre in the UK. It operates two API and intermediate manufacturing facilities, each of which complies with the regulatory requirements in the jurisdictions in which it operates. Between them, these facilities have received approval from various prominent international regulatory bodies.
We are proud to share that Intas’ has been selected by the Government of India for its Production Linked Incentive (PLI) scheme. It will add further impetus to our manufacturing ambitions. We are also boosting manufacturing capabilities and sharpening our focus on indigenous manufacturing of critical products, which our nation is currently importing. Swiftly and steadily, we are shaping up to become Atmanirbhar and a leader in this critical component of the drug supply chain. We will continue to create a world of good health, happiness, and hope.